Market research
LALPATHLAB.NSE Dr. Lal PathLabs Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 310B
- P/E ratio
- 57.29
- Analyst target
- 2018.0769
- Dividend yield
- 0.8%
- Beta
- 0.16
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- INE600L01024
- Market cap
- 310B
- P/E ratio
- 57.29
- Analyst target
- 2018.0769
- Dividend yield
- 0.8%
- Beta
- 0.16
About
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Research context
Dr. Lal PathLabs Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LALPATHLAB.NSE discussion.
5 years, 6 months ago
Dr. Lal PathLabs Limited is currently in a long term uptrend where the price is trading 36.3% above its 200 day moving average.
From a valuation standpoint, the stock is 244.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.5.
Dr. Lal PathLabs Limited's total revenue rose by 38.0% to $5B since the same quarter in the previous year.
Its net income has increased by 74.7% to $945M since the same quarter in the previous year.
Based on the above factors, Dr. Lal PathLabs Limited gets an overall score of 3/5.